目次

Table of Content

1. Introduction To Peptide Drug Conjugates
1.1 Overview
1.2 History and Evolution
1.3 Peptide Drug Conjugates v/s Antibody Drug Conjugates

2. Peptide Drug Conjugates - Structural Components and Mechanism of Action
2.1 Components
2.2 Mechanism of Action

3. Peptide Drug Conjugates Research and Development Trends By Indication
3.1 Cancer
3.2 Others

4. Global Peptide Drug Conjugates Research and Market Trends By Region
4.1 US
4.2 China
4.3 Japan
4.4 Europe
4.5 South Korea

5. Global Peptide Drug Conjugates Market Outlook
5.1 Current Clinical and Market Trends
5.2 Future Market Outlook and Opportunities

6. Peptide Drug Conjugate Development Proprietary Technologies and Methodologies

7. Global Peptide Drug Conjugates Clinical Pipeline Overview
7.1 By Company
7.2 By Country
7.3 By Indication
7.4 By Patient Segment
7.5 By Phase

8. Global Peptide Drug Conjugates Clinical Trials Insight By Company, Country, Indication and Phase
8.1 Research
8.2 Preclinical
8.3 Phase-I
8.4 Phase-I/II
8.5 Phase-II
8.6 Phase-III

9. Marketed Peptide Drug Conjugates Clinical Insight

10. Lutathera - Clinical and Commercial Insight
10.1 Overview, Availability and Patent Insight
10.2 Dosage and Price Analysis
10.3 Sales Analysis

11. Pepaxto/Pepaxti - Clinical and Commercial Insight
11.1 Overview, Availability and Patent Insight
11.2 Dosage Analysis
11.3 Sales Analysis

12. Competitive Landscape
12.1 Angiochem
12.2 Avacta
12.3 Bicycle Therapeutics
12.4 Cybrexa Therapeutics
12.5 ITM Solucin
12.6 Novartis
12.7 Oncopeptides
12.8 PepGen Corporation
12.9 Soricimed Biopharma
12.10 Theratechnologies

List of Figures
Figure 1-1: Timeline of Key Events in Development of Peptide Drug Conjugates
Figure 2-1: Peptide Drug Conjugates - Components
Figure 2-2: Peptide Drug Conjugate - Mechanism Of Action
Figure 3-1: Approved Peptide Drug Conjugates
Figure 3-2: TH1902-CTR-0001 Phase I (NCT04706962) Study - Initiation and Completion Year
Figure 3-3: CBX-12-101 Phase I/II (NCT04902872) Study - Initiation and Completion Year
Figure 3-4: CBX-12-201 Phase II (NCT06315491) Study - Initiation and Completion Year
Figure 3-5: Duravelo-1 Phase I/II (NCT04561362) Study - Initiation and Completion Year
Figure 3-6: Duravelo-2 Phase II/III (NCT06225596) Study - Initiation and Completion Year
Figure 3-7: Duravelo-3 Phase II (NCT06840483) Study - Initiation and Completion Year
Figure 3-8: Duravelo-4 Phase II (NCT06933329) Study - Initiation and Completion Year
Figure 3-9: BT5528-100 Phase I/II (NCT04180371) Study - Initiation and Completion Year
Figure 3-10: ALS-6000-101 Phase I (NCT04969835) Study - Initiation and Completion Year
Figure 5-1: Global - Peptide drug Conjugates Market (US$ Million), 2018-2025
Figure 5-2: Global - Peptide drug Conjugates Market (US$ Million), 2025-2030
Figure 5-3: Potential Future Directions in Peptide-Drug Conjugate Development
Figure 6-1: Alphalex Platform - Cybrexa
Figure 6-2: Decoy Platform - Candidate Life Cycle
Figure 6-3: Decoy Platform - Modular Peptide Engineering and Conjugation Chemistry
Figure 6-4: Decoy Platform - Features
Figure 6-5: EDO Platform - Drug Structure
Figure 6-6: OncoPDCs - Excellamol
Figure 6-7: PDPS Platform - PeptiDream
Figure 6-8: Rational Design Based Drug Discovery - Mainline Biosciences
Figure 6-9: pre|CISIONandreg; Platform - Generations and Features
Figure 6-10: PIP - Mechanism of Action
Figure 6-11: PIP Platform - TwoStep Toolbox
Figure 6-12: Peptide - Advantages
Figure 6-13: SORT1+ Technology - PDC Structure
Figure 6-14: MPD-1 - Mechanism of Action
Figure 6-15: Bi-XDC Technology - Coherent Biopharma
Figure 6-16: NIPEP-TPP - NIBEC
Figure 7-1: Global - Peptide Drug Conjugate Clinical Pipeline by Company (Number of Drugs), 2025 Till 2030
Figure 7-2: Global - Peptide Drug Conjugate Clinical Pipeline by Country (Number of Drugs), 2025 Till 2030
Figure 7-3: Global - Peptide Drug Conjugate Clinical Pipeline by Indication (Number of Drugs), 2025 Till 2030
Figure 7-4: Global - Peptide Drug Conjugate Clinical Pipeline by Patient Segment (Number of Drugs), 2025 Till 2030
Figure 7-5: Global - Peptide Drug Conjugate Clinical Pipeline by Phase (Number of Drugs), 2025 Till 2030
Figure 10-1: Lutathera - Approval Year by Region
Figure 10-2: Lutathera - Patent Filing and Expiration Year
Figure 10-3: Global - Lutathera Sales (US$ Million), 2018-2025
Figure 10-4: Global - Lutathera Quarterly Sales (US$ Million), 2025
Figure 10-5: Regional - Lutathera Sales (US$ Million), Q1’2025
Figure 10-6: Regional - Lutathera Sales (US$ Million), Q1’2025
Figure 10-7: Global - Lutathera Quarterly Sales (US$ Million), 2024
Figure 10-8: US - Lutathera Quarterly Sales (US$ Million), 2024
Figure 10-9: US - Lutathera Sales (US$ Million), 2023-2025
Figure 10-10: ROW - Lutathera Quarterly Sales (US$ Million), 2024
Figure 10-11: ROW - Lutathera Sales (US$ Million), 2023-2025
Figure 11-1: Pepaxto/Pepaxti - Approval Year by Region
Figure 11-2: Pepaxti - Patent Filing and Expiration Year
Figure 11-3: Europe - Pepaxti Sales (US$ Million), 2021-2025

List of Tables
Table 1-1: Antibody Drug Conjugates v/s Peptide Drug Conjugates
Table 10-1: Lutathera - Recommended Amino Acid Solution Dosing
Table 10-2: Lutathera - Recommended Dosage Modifications for Adverse Reactions
Table 11-1: Pepaxti - Recommended Dose Reduction for Adverse Reactions
Table 11-2: Pepaxti - Recommended Dose Modifications for Adverse Reactions